Editorial: Use of Cesium-131 radioactive seeds in prostate permanent implants

Journal of Medical Physics

Volumn 34, Issue 4, 2009, Pages 191-193

  Kehwar, T S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CESIUM; CESIUM 131; GOLD; IODINE 125; PALLADIUM 103; RADIOISOTOPE; TITANIUM; UNCLASSIFIED DRUG;

CANCER CELL; CERAMICS; DRUG HALF LIFE; EARLY CANCER; EDEMA; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMPLANT; INTERSTITIAL RADIATION; MONOTHERAPY; PERMANENT PROSTATE SEED IMPLANTATION; PRESCRIPTION; PROSTATE; PROSTATE CANCER; PROSTATE PERMANENT SEED IMPLANT; PROSTATIC EDEMA; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOBIOLOGY; URETHRA;

EID: 70349811183     PISSN: 09716203     EISSN: 19983913     Source Type: Journal    
DOI: 10.4103/0971-6203.56077     Document Type: Editorial

References (11)

1. Paschkis R, Tittinger W. Radium behandlung eines prostatasarkoms. Wein Klin Wochenscher 1990;48:1715-1716
2. Barringer BS. Carcinoma of the prostate. In: Bagg HJ, Bailey HC, Barringer BS, et al, editors. Radium report of the Memorial Hospital. New York, NY: Paul B. Hoeber; 1924. p. 174-191
3. Grimm PD, Blasko JC, Radge H. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early-stage prostate cancer-technical concepts in planning, operative technique, and evaluation. Atlas Urol Clin N Am 1994;2:113-125
4. Henschke UK, Lawrence DC. Cesium-131 seeds for permanent implants. Radiology 1965;85:1117-1119
5. Bice WS. Cesium-131: Ready for prime time? Brachytherapy 2009;8:1-3.
6. Smith R P, Jacobs BL, Beriwal S, Gibbons E P, Benoit RM. Description and predictive factors of urinary toxicity following prostate brachytherapy using 131Cs. Brachytherapy 2009;8:172-173
7. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson J F, Meigooni AS. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No 43: American Association of Physicists in Medicine. Med Phys 1995;22:209-234
8. Wang J, Zhang H. Dosimetric characterization of model Cs-1 Rev2 cesium-131 brachytherapy source in water phantoms and human tissues with MCNP5 Monte Carlo simulation. Med Phys 2008;35:1571-1579
9. Kehwar TS, Jones HA, Huq MS, Beriwal S, Benoit RM, Smith R P. Effect of edema associated with 131Cs prostate permanent seed implants on dosimetric quality indices. Med Phys 2009;36:3536-3542
10. Armpilia CI, Dale RG, Coles I P, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys 2003;55:378-385
11. Bice WS, Prestidge BR, Kurzman S, Beriwal S, Moran BJ, Patel RR, et al. Recommendations for permanent prostate brachytherapy with 131Cs: A consensus report from the Cesium Advisory Group. Brachytherapy 2008;7:290-296